Monday, 19 February 2018 - 8:40
  • it
  • de
  • en
  • fr

M&A

Novartis starts divesting Sandoz’s North-American business ($1.6bn)

Reuters yesterday announced that Switzerland-based Novartis has started the process to divest the North-American division of Sandoz, its generic pills business. The divestiture may attract other drugmakers and private equities, ready to offer a minimum of $1.6bn, that is 8x…

LyondellBasell acquires A. Schulman for $2.25bn

Chemicals multinational LyondellBasell has announced today it has acquired US-based A. Schulman, Inc. for $2.25bn. The acquisition strengthens LyondellBasell’s position in the plastics business, adding new composites and high-performance polymers to its pipeline. The price paid by LyondellBasell corresponds to…

Roche pursuing M&A again: Flatiron Health acquired for $1.9bn

Switzerland-based multinational Roche announced yesterday evening, after trading closed, that it has acquired Flatiron Health for $1.9bn. Flatiron is a start-up focusing on cancer treatment technology, developing tools such as the electronic health record (EHR) software and real-world evidence for…

Bristol-Myers Squibb enters into $3.6bn agreement with Nektar Therapeutics

Bristol-Myers Squibb is pursuing M&A again: yesterday, in the late evening, it announced an agreement with Nektar Therapeutics, expanding the existing strategic collaboration agreement signed in 2016 by the two companies for the scientific and commercial development of immunotherapy NKTR-214…

Astellas announces acquisition of Universal Cells for $102.5m

Japan-based Astellas Pharma has announced today to the Japanese stock exchange authorities that it has acquired Universal Cells for $102.5m. Universal Cells is headquartered in Seattle and, over the years, has developed the Universal Donor Cell technology, based on stem…

Galapagos tries to avoid being acquired by Gilead

The Dutch economic and financial daily Het Financieele Dagblad has published today a front-page article reporting that Belgium-based biotech Galapagos is looking for an important shareholder protecting it from Gilead. Gilead already owns 13% of the company. Galapagos CEO Van…

Amgen still far from performing an important acquisition

CFO of the US-based biotech group Amgen, David Meline, has said in an interview that, despite his team’s commitment in researching for a valid M&A candidate, it has not come up with any results yet, due to the companies’ current…

Allergan acquires Elastagen for $95m

Allergan has acquired Elastagen for $A120m ($95m). Elastagen is a spin-off of the University of Sydney focusing on acne scars treatments. Elastagen’s technology is based on human tropoelastin (the precursor of elastin). Elastagen two years ago obtained $13m in funding….

Croda – Ashland merger fails

Reuters has reported that UK-based Croda has interrupted its talks for a merger of equals with US-based Ashland Global Holdings. Ashland has been considered a potential acquisition target for months, having shown a consolidation trend in the polymers and specialty…

Sanofi wins Battle over Belgium’s Ablynx through €3.9bn offer

Sanofi has won the battle over Ablynx, beating its competitor Novo Nordisk that offered €2.6bn for the Belgium-based biotech two weeks ago. Sanofi has offered €3.9bn, notching the second significant acquisition in the Oliveir Brandicourt era, after taking over Bioverativ…

Battle over Ablynx begins

Bloomberg has reported that Denmark-based Novo Nordisk is preparing a new bid to acquire Belgium-based biotech Ablynx. The offer would significantly improve the previous one-€2.6bn-and could be submitted as early as next week. Ablynx has tried to enter into talks…

Biogen announces quarter results exceeding expectations and shares soar

The fiscal reform introduced by the Trump Administration has given impetus to a new, incredible M&A season in the US pharma sector. Biotech company Biogen today has announced it has acquired for $217m Karyopharm’s investigational therapy KPT-350, for the treatment…

Sabic purchases 25% in Clariant

Investor White Tale has sold its stake in Clariant to Saudi Arabia-based group Sabic, which becomes the largest shareholder of the Swiss group with approximately 25% of shares, currently worth about CHF2.3bn. Importantly, Sabic and Clariant are already partners in…

Novartis to pay $170m for Spark Therapeutics’ gene therapy

Novartis’ new CEO Vas Narasimhan appears to be fulfilling the promises made when he was appointed, as he announced he was determined to invest on gene therapies. Novartis announced yesterday night that it has acquired the commercialization rights outside the…

New extraordinary M&A season started in pharma sector

The healthcare business has seen acquisitions for a total approaching $30bn only within the first three weeks of the year–a level never reached since when the crisis started in 2007. One of the key factors for this spate of M&A…

Celgene acquires Juno Therapeutics for $9bn

As everyone expected, Celgene has acquired biotech company Juno Therapeutics for $9bn, that is $87 per share, or a 91% premium over the share price before it was announced that Celgene was targeting Juno (January 16th). The deal gives Celgene…

Confirmed: Sanofi buys Bioverativ for $11.6bn

Sanofi has announced today in the morning, before trading started, that it has acquired US-based Bioverativ for $11.6bn in cash, corresponding to $105 per share, that is a 64% premium over Friday night’s closing price. The deal enhances Sanofi’s hemophilia…

Sanofi about to acquire Bioverativ for $11.5bn (63% premium)

The Wall Street Journal yesterday reported, late at night, that France-based Sanofi is about to acquire Bioverativ Inc. for approximately $11.5bn, that is $105 per share, which would correspond to a 63% premium over last Friday’s closing price. Investors in…

Biogen and UCB targeting Acorda Therapeutics (€1bn)

US-based Acorda Therapeutics (New York) is reportedly targeted by Belgium-based UCB, the Belgian daily De Tijd has reported today. Acorda Therapeutics is worth approximately $1bn, according to analysts (Bloomberg). Due to pressure by shareholders, Acorda’s management in August put the…

Analysts don’t approve of Celgene’s takeover to Juno Therapeutics

Analysts are assessing Celgene’s potential takeover to Juno. Despite their different views, all experts agree that the acquisition will be very expensive ($8-$10bn) and will not provide any short-term solution to Juno’s issues. Juno Therapeutics offers Celgene the opportunity to…

Celgene about to acquire Juno Therapeutics ($5.5bn)

Celgene’s M&A season seems to never end. Few days after acquiring Impact Biomedicines for $1.1bn in cash, the US-based biotech company headquartered in New Jersey is in advanced talks to acquire Juno Therapeutics, worth at least $5.5bn. By acquiring Juno,…

Battle over Sanofi’s Zentiva ($2bn) begins

The Economic Times India yesterday reported that India-based Aurobindo, Zydus Cadila, Torrent Pharma and Intas are targeting Sanofi’s European generics business, which is managed by Czech subsidiary Zentiva. Zentiva is worth at least $1.5-$2.0bn, according to analysts, and has drawn…

GSK seeks to protect Advair through GBP1.2bn acquisition of Vectura

The British newspaper The Telegraph has reported today that the pharma giant GSK is about to offer GBP1.2bn for UK-based Vectura. The reported offer corresponds to GBP1.75 per share, that is a 53% premium over yesterday’s closing price. A takeover…

Novo Nordisk offers €2.6bn for Belgium-based Ablynx

The Belgian biotech sector appears to be fairly attractive to the big pharma. After last Friday’s announcement that Takeda had acquired Belgium-based Tigenix for €520m, Denmark-based Novo Nordisk has announced today it has offered €2.6bn for Belgian biotech company Ablynx….

Acquisition of Italy’s Esaote (>€300m) by Chinese consortium at risk

Italian economic-financial daily Il Sole 24 Ore reported yesterday that the acquisition of Italy-based Esaote by a Chinese consortium could be at risk. More specifically, the Italian Government, shareholder in the Genoa-headquartered company, could use its so-called “golden power” in…